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Simple Summary: Here, we monitored the course of the disease and treatment of sinonasal melanoma
patients. Since treatment options are rare, immunotherapy is often the treatment of choice. However,
intrinsic or acquired resistance to treatment may occur. We assessed the mutational status of the
tumors and metastases during the course of therapy and recognized a switch of the oncogenic drivers
to mutant NRAS in progressing disease. As a switch of drivers (other than the addition of a second
driver) has not been reported yet, longitudinal molecular testing and the awareness of molecular
heterogeneity of sinonasal melanoma is crucial.
Abstract: Mucosal melanoma can be driven by various driver mutations in genes such as NRAS, KIT,
or KRAS. However, some cases present with only weak drivers, or lacking known oncogenic drivers,
suggesting immunotherapy over targeted therapy. While resistance mechanisms to immunotherapy
in cutaneous melanoma have been uncovered, including alterations in JAK1/2, B2M, or STK11, a
switch of oncogenic drivers under immunotherapy has not yet been observed. We report three
cases of metastatic sinonasal melanoma that switched oncogenic drivers from KRAS, KIT, or no
driver to NRAS during or after immunotherapy, thereby showing progressive disease. One of the
cases presented with three spatially separate driver mutations in the primary tumor, whereas the
NRAS clone persisted under immunotherapy. In comparison, three different control cases receiving
radiotherapy only did not show a change of the detectable molecular drivers in their respective
recurrences or metastases. In summary, these data provide an important rationale for longitudinal
molecular testing, based on evidence for an unforeseen recurrent event of molecular driver switch to
NRAS in progressing sinonasal melanoma. These findings provide the basis for further studies on a
potential causal relation of emerging NRAS mutant clones and immunotherapy.
Keywords: mucosal melanoma; sinonasal cancer; oncogenic driver; immunotherapy; tumor hetero-
geneity; disease monitoring
1. Introduction
Sinonasal melanoma is a rare melanoma subtype (0.5 cases per Mio/year) [1]. While
treatment options for cutaneous melanoma emerged in recent years due to the success-
ful implementation of targeted therapy and immunotherapy (IT) [2], the treatment of
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metastatic sinonasal melanoma remains challenging. Molecular targets for therapy are
infrequent [3], and little is known about responses to immunotherapy [1]. Therefore,
metastatic sinonasal melanoma patients are currently treated according to the guidelines
for cutaneous melanoma [4]. Besides immunotherapy, targeted therapy with imatinib
or nilotinib are options in patients with KIT mutations [5,6] or binimetinib for patients
harboring NRAS mutations [7]. Zaretsky et al. recently reported the acquirement of loss-of-
function mutations in JAK1/2 or B2M, causing an interruption of the interferon gamma
signaling or loss of MHC-I surface expression, respectively, leading to resistance to anti-PD-
1 treatment [8]. As resistance mechanisms to targeted therapy with BRAF/MEK inhibitors,
mutations in MAP2K1/2, alternative splice variants of BRAF, BRAF amplifications or a
gain of NRAS mutations were detected [9,10]. However, the emergence or selection of
NRAS-mutant clones in progressing disease has not been shown yet. We report three cases
of sinonasal melanoma, initially harboring KRAS, KIT, or no detectable driver mutation.
For the first time, we describe a switch from the initial distinct oncogenic drivers (or no
detectable driver) to solely NRAS in the course of therapy.
2. Materials and Methods
Collection of patient material: The local ethics review board approved this study
(BASEC 2020-01663, approved: 30 July 2020) and written informed consent was obtained
(BASEC PB_2017-00494, amendment approved: 25 July 2017). Molecular data from the
primary tumor of patient 2 and of RT-patient 2 were previously published [3].
Collection of clinical data: All patients were presented regularly at the multidisci-
plinary tumor board. Clinical workup included molecular analysis to search for driver
mutations and possible therapeutic targets. All patients were re-sequenced during the
course of metastatic disease.
Molecular analysis: For Next Generation Sequencing, patient material was reviewed
by an attending pathologist and the area of interest was marked on a hematoxylin and
eosin (H&E) slide. Punch biopsies were then taken from the corresponding FFPE tissue
block and DNA was isolated using the Maxwell 16 FFPE Tissue LEV DNA Purification
Kit (Promega, Madison, WI, USA). For detection of low frequency mutations with the
Oncomine™ Colon cfDNA assay (see below), DNA was isolated from whole sections of
the FFPE tumor blocks. DNA was quantified using a fluorometric assay (Qubit, Thermo
Fisher Scientific, Waltham, MA, USA). Library preparation was performed using the KAPA
HyperPlus Kit (Roche, Basel, Switzerland) according to the manufacturer’s manual. Target
capture was performed according to the protocol using a customized probe set (KAPA
Hyper Choice, Roche) covering 190 melanoma-typical genes (Table S1) and heterozygous
SNPs across the genome to detect copy number changes. HLA-A, HLA-B, and HLA-C loci
were covered to conduct HLA typing. The tumor mutational burden (TMB) was calculated
using all non-synonymous coding mutations divided by the size of the coding target region
of the panel. All libraries were sequenced paired-end (100 bp) on an Illumina NextSeq550
sequencer. Data analysis was performed using a customized pipeline and open-source
software [3].
For liquid biopsy, cell-free DNA (cfDNA) was isolated from 2 mL of plasma using the
QIAamp circulating nucleic acid kit (Qiagen, Hilden, Germany). The DNA was quantified
using a fluorometric assay (Qubit, Thermo Fisher Scientific). NGS on liquid biopsies, as
well as NGS on whole sections of the tumors was performed using the Oncomine™ Colon
cfDNA Assay (Thermo Fisher Scientific). The libraries were templated and loaded on a
540er chip using the Ion Chef™ instrument (Thermo Fisher Scientific) and sequenced on
the Ion S5™ sequencer (Thermo Fisher Scientific). The data were analyzed using the Ion
Reporter software version 5.12 (Thermo Fisher Scientific).
Variant reporting focused on main melanoma drivers (MAPK pathway) and potential
resistance mutations to approved therapies (e.g., PIK3CA/mTOR pathway).
Histology/Immunohistochemistry: FFPE specimen of 2 µm were stained with hema-
toxylin and eosin for morphological assessment. Immunohistochemistry was performed
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using the Bond III automated staining system (Leica), and the monoclonal anti-NRAS
(mutated Q61R) antibody SP174 (Abcam, Cambridge, UK). For NRAS staining, pretreat-
ment with H2 was done for 60 min. The recombinant anti-rabbit monoclonal anti-NRAS
(mutated Q61R) antibody SP174 (Abcam) was used in a 1:50 dilution. Detection was
performed using the Bond Polymer Refine Red Detection Kit (Leica, Wetzlar, Germany).
Staining of CD8 and PD-L1 was performed as described previously [3]. The morpholog-
ical features were evaluated by an experienced head and neck pathologist (NJR). PD-L1
immunohistochemistry was scored as described previously [3]. Numbers of CD8+ T cells
were semi-quantitatively assessed (no, low, moderate, high infiltration) in two locations:
intratumoral and tumor margin.
FDG-PET/CT: Patients underwent several FDG-PET/CT examinations on different
scanners (all manufactured by GE Healthcare, Waukesha, WI, USA).
Dissimilarity and co-ancestry analysis: Dissimilarities were calculated using biallelic
SNPs, usually used for CNV analysis, in addition to the 190 MelArray genes. In total, we
genotyped 22,246 loci across all chromosomes.
3. Results
3.1. Patient History Shows Emergence and Selection of an NRAS-Mutant Clone during the Course
of Immunotherapy
3.1.1. Case 1
This 68-year-old male patient (Figure 1A) presented with progressing pressure sen-
sation in the left cheek and orbita. The staging FDG-PET/CT revealed a large, FDG-avid
mass in the left ethmoid infiltrating in the cribriform plate and showed absence of regional
or distant metastases (Figure 1B). The resection specimen (Figure 1B, left) revealed a KRAS
p.G12R mutation. Interestingly, the dural part of the tumor (Figure 1B, middle) revealed a
KIT p.D816H mutation. The multidisciplinary tumor board opted for adjuvant proton beam
therapy with 72 Gy. Due to local progression three months later (Figure 1C), immunother-
apy with ipilimumab/nivolumab was initiated. Follow-up MRI and FDG-PET/CT after
three months showed local tumor response (Figure 1D, left), but liver metastases, which
were confirmed by biopsy (Figure 1D, middle and right). One month later, NGS of a liquid
biopsy revealed an NRAS p.Q61R mutation. Retrospectively, the NRAS mutation had
not been present in the liver biopsy, which was corroborated by negative staining of the
NRAS Q61R antibody (Figure 1D, insert). However, when staining all available blocks
from the primary tumor, a minute portion of cells were positive for the NRAS Q61R anti-
body (Figure 1B, right, insert). Systemic treatment was changed to nivolumab/relatlimab.
Subsequent metastases in the bone and lung were additionally treated with stereotactic ra-
diation. Owing to local tumor progression and distant metastases, treatment was changed
to dabrafenib/trametinib three months later. An excised soft tissue metastasis of the left
flank confirmed the previously detected NRAS mutation. Thus, the patient is currently
being treated with pembrolizumab/trametinib.
3.1.2. Case 2
This 73-year-old male patient (Figure 2A) presented with watery discharge from the
right nostril, pressure on the right eye, and double vision. An MRI scan revealed a mass
in the right-sided nasal cavity and maxillary sinus, extending into the orbita and anterior
skull base. Biopsy revealed a sinonasal melanoma without regional or distant metastases
on FDG-PET/CT (Figure 2B). NGS showed a KRAS p.G12A mutation and amplification.
Transnasal-transcribriform resection was carried out, followed by intensity-modulated
radiation therapy with 70 Gy. On follow-up PET/CT, there was no evidence of local tumor
recurrence, but multiple new neck lymph node metastases and distant metastases were
found (Figure 2C). A combination of ipilimumab/nivolumab was initiated and after four
cycles switched to nivolumab monotherapy (11 cycles). Follow-up PET/CT four months
after the start of monotherapy showed complete remission (CR) (Figure 2D). A liquid
biopsy taken three months after CR revealed no KRAS or NRAS mutation. This result can
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either indicate sustained remission or absence of tumor DNA in the blood for other reasons.
More than one year after initiation of immunotherapy, the patient developed a mass in the
right nasal cavity, visible both clinically and on PET/CT. No other tumor manifestation
was found. Tumor recurrence was confirmed (Figure 2E) and nivolumab treatment was
continued. NGS of the biopsy revealed an NRAS p.Q61K mutation. Six months later, a
subtotal tumor removal was anticipated due to progression. Treatment with trametinib
will be started as the NRAS mutation is still evident.
 
Figure 1. Course of disease, treatment, and morpho-molecular workup of patient 1. (A) Timeline. (B) Histology of the
primary tumor, including NRAS Q61R immunohistochemistry (inserts); left: KRAS mutant region, middle: KIT mutant
region, right: NRAS mutant region; PET MIP display and fused PET/CT image at primary diagnosis. (C) T1-weighted
contrast-enhanced and fat-suppressed MR image at local progression (long arrows: sinonasal tumor mass, short arrows:
intraorbital extraconal tumor mass, arrowheads: dural enhancement. (D) MR image at local regression (arrows/arrowheads:
see above), histology of the liver biopsy, including NRAS Q61R immunohistochemistry (insert); PET MIP display and fused
PET/CT image before liver biopsy. (E) Histology of the soft tissue metastasis, including NRAS Q61R immunohistochemistry
(insert); PET MIP display and fused PET/CT image at progression under kinase inhibitors. Scale bar: 40 µm. wt: wild type.
 
Figure 2. Course of disease, treatment, and morpho-molecular workup of patient 2. (A) Timeline. (B) Histology of the
primary tumor; PET MIP display and fused PET/CT image at primary diagnosis. (C) PET MIP display and fused PET/CT
image at the start of immunotherapy. (D) PET MIP display and fused PET/CT image at CR. (E) Histology of the first local
recurrence, left: spindle cell shaped morphology, right: monomorphic epithelioid morphology; PET MIP display and fused
PET/CT image at first local recurrence. (F) Histology of the second local recurrence; PET MIP display and fused PET/CT
image at second local recurrence. Scale bar: 40 µm. wt: wild type, CR: complete remission.
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3.1.3. Case 3
This 72-year-old male patient (Figure 3A) underwent surgery of a left-sided endonasal
tumor. Histological workup revealed an amelanotic melanoma (Figure 3B), which had
no evident driver mutation, but mutations in JAK2 and MITF. For the next two years, the
patient underwent various treatment lines that were continuously adjusted depending on
disease progression monitored by FDG-PET/CT (Figure 3A).
 
Figure 3. Course of disease, treatment, and morpho-molecular workup of patient 3. (A) Timeline. (B) Histology of the
primary tumor; PET MIP display and fused PET/CT image at primary diagnosis. (C) Histology of the lymph node
metastasis; PET MIP display and fused PET/CT image at progression after 34 cycles of pembrolizumab. (D) Histology of
the colon metastasis; PET MIP display and fused PET/CT image at progression under nivolumab/relatlimab. (E) PET MIP
display and fused PET/CT image at CR. (F) Histology of the adrenal gland metastasis; PET MIP display and fused PET/CT
image at progression without therapy. Scale bar: 40 µm. wt: wild type, LN: lymph node, CR: complete remission.
Forty-eight months after initial diagnosis, a left-sided cervical lymph node metasta-
sis was resected (Figure 3C) and sequenced, which revealed a mutational profile similar
to the primary tumor. Due to a progressing metastasis in the cecum, treatment with
nivolumab/relatlimab was started. After five months under immunotherapy this lesion
was removed surgically (Figure 3D), and molecular analysis revealed a PIK3CA p.C420R
mutation together with the known JAK2 and MITF mutations. Systemic treatment was
discontinued, and another mesenteric lymph node metastasis was irradiated. Thereafter,
the patient was considered to be in CR (Figure 3E). Seven months later, a left-sided adrenal
gland metastasis was removed surgically (Figure 3F) and confirmed by immunohisto-
chemistry. Molecular analysis revealed an NRAS p.Q61K mutation and the known MITF
mutation, but no JAK2 mutation. Owing to disease progression, the patient is currently
under treatment with ipilimumab/nivolumab.
3.2. Mutational Analysis of Different Tumors Reveals Both Intra-Patient Similarities and
Molecular Differences
We analyzed heterozygous SNPs across the genome of all tumors, which revealed the
relationship of all tumors within each patient. Of note, intra-patient heterogeneity could
also be observed (Figure S1).
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For each patient we intersected the set of all mutations found in the tumors. Tumors of
patient 1 had an overlap of 46.2% (six mutations; Figure S2A). Tumors of patient 2 had an
overlap of 33.3% (four mutations; Figure S2B), whereas additional 25.0% (three mutations;
Figure S2B) overlapped between the two NRAS-mutant tumors. The four tumors of patient
3 had an overlap of 48.1% (13 mutations; Figure S2C). When overlapping the mutations
of NRAS-mutant tumors from all patients, there were no similarities of the mutational
profile between the different patients (Figure S2D). The mutational profile of all tumors is
provided in Tables S2–S4. The mutation frequency in synopsis with the tumor cell content
revealed the presence of the NRAS mutation on one allele, excluding subclonal events.
3.3. NRAS Clones either Preexisted or Emerged during the Course of Disease and Therapy
To investigate whether the NRAS mutations were already present in the tumor before
immunotherapy on a subclonal level, we searched for a low frequency presence of the
NRAS mutations in the sequencing data from the investigated tissue punches (mean
coverage of coding target region: patient 1: 168x (primary diagnosis) and 791x (extensive
resection); patient 2: 757x; patient 3: 1371x) but did not find any. Conversely, NRAS-mutant
tumors did not show any low-frequency traces of the previously detected KRAS, KIT or
PIK3CA mutations in the NRAS mutant tumors of all patients (mean coverage of coding
target region: patient 1: 710x; patient 2: 290x and 1077x; patient 3: 1720x). For the detection
of the NRAS mutation in the melanoma of patient 1 (NRAS p.Q61R), a specific antibody
is available. This NRAS Q61R antibody revealed no positivity in the KRAS-mutant or
KIT-mutant part of the primary tumor of patient 1 (Figure S3). However, a minute region
was positive in another part, indicative for the NRAS mutation. To further investigate this
molecular heterogeneity, whole sections of the tumor tissue before immunotherapy were
selected and sequenced with a small but highly sensitive NGS panel (Oncomine™ Colon
cfDNA Assay) that includes HotSpot regions of NRAS and KRAS (Table 1).
Table 1. High sensitivity NGS analysis of whole tumor sections before immunotherapy.
















covered by the assay
Patient 2 KRAS p.G12A 64.21% 992x 70%
Patient 3 WT 30%
WT = wild type.
The tumor of patient 1 revealed the previously detected KRAS p.G12R mutation
(frequency: 4.6%), confirmed the NRAS p.Q61R mutation, previously detected using the
corresponding antibody (frequency: 3.3%), and revealed an additional NRAS p.G12V
mutation (frequency: 7.0%). These findings indicate a molecularly heterogeneous tumor
with different subclones (tumor cell content of the whole section: 40%). The previously
detected KIT mutation is not covered by the target region of the selected panel. The tumor
of patient 2 revealed a high proportion of KRAS p.G12A mutated cells (64.2%), concordant
with our previous results and reflecting an amplification of the mutant allele, but no NRAS
mutation (tumor cell content of the whole section: 70%). The tumor of patient 3 showed no
mutation in NRAS (tumor cell content of the whole section: 30%). MITF and JAK2 are not
covered by the selected panel.
As all patients underwent additional radiotherapy (RT) during their course of disease,
we investigated whether the emergence of the NRAS mutation could be an effect of this
therapy. We retrospectively identified a control group of sinonasal melanoma patients
who underwent solely radiotherapy (n = 3). Primary tumors and tumor recurrences or
metastases of these three patients before and after radiotherapy were sequenced, whereas
no emerging NRAS mutation was detected (Table S5).
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3.4. Tumor Morphology Revealed No Association with Mutational Status or Response to Therapy
Furthermore, we compared the morphology of the different tumors (Figures 1–3
histological pictures, Table 2). The initial KRAS-mutated melanoma of patient 1 (Figure 1B,
left) showed only minor differences to the KIT-mutated and NRAS-mutated part of the
tumor (Figure 1B, middle, right). The NRAS-mutated soft tissue metastasis showed a
similar morphology, however with obvious chromatin clearing of the nuclei (Figure 1E),
while the liver biopsy showed only few vital cells (Figure 1D).































































































































LN = lymph node, WT = wild type, major differences are printed in bold.
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The initial KRAS-mutated melanoma of patient 2 (Figure 2B) showed differences in
cell size and morphology compared to the first local recurrence, which had a biphasic
appearance (Figure 2E), while the second local recurrence (Figure 2F) was similar to the
initial tumor.
For patient 3, all manifestations presented a similar morphology (Figure 3B–D), with
the NRAS-mutant tumor showing smaller cells and lacking the initial prominent nucleoli
(Figure 3F).
When comparing the NRAS-mutant tumors of the three patients, their morphology
did not reveal a distinctive mark to identify this molecular subtype.
3.5. CD8+ T Cell Infiltration, PD-L1 Expression and Tumor Mutational Burden (TMB) Do Not
Correlate with Therapy Outcome
The tumors before immunotherapy of the responding patients (patients 1 and 2)
showed no or only low intratumoral infiltration of CD8+ cells with low to moderate
accumulation at the tumor margins, while NRAS mutant tumors emerging under therapy
showed moderate intratumoral infiltration and moderate to high accumulation of CD8+
cells at the tumor margins. PD-L1 expression was constantly negative or weak in tumors
from both patients before and after therapy. The tumor before IT of the intrinsic resistant
patient (patient 3) showed a moderate intratumoral infiltration of CD8+ cells with a high
number of cells at the tumor margin, while the NRAS mutant tumor showed only single
intratumoral CD8+ infiltrating cells with moderate presence at the tumor margin. PD-L1
expression was high in both tumor and immune cells before and after therapy (Figure S4).
In summary, NRAS mutant tumors of the initially responding patients showed a slightly
higher CD8+ accumulation in the tumor and at its margins, while the NRAS mutant tumor
of the intrinsic resistant patient showed a decreased infiltration compared to the WT tumors
(Table S6).
Moreover, we calculated tumor mutational burden (TMB) based on our MelArray
NGS panel (Table S7). Patients 1 and 2 that initially responded to the treatment had a lower
TMB than the intrinsic resistant patient 3. Thus, higher TMB does not seem to correlate
with response to IT in our cases.
4. Discussion
We have documented the evolution of metastatic sinonasal melanoma in three pa-
tients receiving combinational immunotherapy with nivolumab. While two patients
(patients 2 and 3) lacked molecular intra-patient heterogeneity before immunotherapy,
harboring only a KRAS mutation or no evident driver mutation, the primary tumor of
patient 1 showed a heterogeneous molecular profile with several different clones and differ-
ent driver mutations. Both patients 1 and 2 initially responded to immunotherapy, whereas
the relapse showed presence of mutant NRAS. While the mutation was not detectable in
the pre-treatment lesion of patient 2 performing a highly sensitive assay, it seemed to be the
dominant, and therefore metastasizing, clone in patient 1. In patient 2, the NRAS mutant
local recurrence appeared one year after the start of IT with ipilimumab/nivolumab, while
the patient was in CR for already 6 months but still under nivolumab treatment. In patient
1 the NRAS mutant clone was present in the liquid biopsy four months after treatment
initiation and in the later occurring soft tissue metastasis, while the other initially detected
drivers were missing. Retrospectively, the NRAS mutation was already present on a sub-
clonal level in the primary tumor. Patient 3 had intrinsic resistance to immunotherapy and
CR was only reached due to surgery and RT. However, no NRAS clone was detectable in
the tumor prior to IT, suggesting its emergence after therapy. While the NRAS mutation
appeared under IT or in close proximity to the end of IT in the first two patients, it occurred
late in patient 3 with one year after stop of IT without any further treatment. As this patient
had an intrinsic resistance to the IT, it cannot be clarified whether the NRAS mutation is
directly related to the treatment.
To investigate whether the NRAS mutation occurred as a potential effect of radio-
therapy (RT), that all patients received at one point during their course of disease, we
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sequenced tumors before and after RT, but did not find an occurring NRAS mutation.
Given the rarity of sinonasal melanoma, it is difficult to find a larger group of patients
with archived samples before and after a certain treatment. Therefore, our results indicate
the occurrence of the NRAS mutation rather in the context of immunotherapy than of RT.
However, statistical evidence is lacking due to the small cohort size. Nevertheless, we
can state that this phenomenon occurred recurrently under real world conditions and is
therefore important to know. Further, this finding is very unlikely to occur recurrently in
three independent patients of this rare tumor entity just by chance.
Neither clinically nor on FDG-PET/CT did we find lesions suspicious for a second
primary tumor that would possibly explain the detection of different oncogenic drivers.
While tumor heterogeneity in melanoma is well known, a switch of the driver mutation
or a selection for a specific driver mutation in the course of immunotherapy as a possible
mechanism of therapy resistance has not been reported yet. It was shown for several cancer
types, that intra-patient tumor heterogeneity is limited to passenger mutations, with a
consistent main driver in all metastases [11–13]. Moreover, when acquiring an additional
driver mutation, the initial driver remains present, even within the same tumor cell [14].
Only one study compared primary cutaneous melanoma and corresponding metastases
and showed the detection of emerging NRAS mutations in two patients. However, no infor-
mation about treatment of these two patients is available [15]. Due to known intratumoral
molecular heterogeneity in melanoma, it can be difficult to assess the mutational status of
the whole tumor. NGS results on punch biopsies are potentially biased in tumors with high
intratumoral heterogeneity. This was especially evident in patient 1, where we only found
a KRAS mutation in a punch from the primary resection of the tumor, and afterwards a KIT
mutation in the extensive resection of the same tumor. Moreover, an NRAS mutation be-
came evident in another part of this tumor after using a specific antibody for this mutation.
To reduce the bias, whole sections of a tumor or even pooled whole sections of different
FFPE blocks of a tumor, instead of punches, can be sequenced. In this way, we were able to
detect several clones within the primary tumor of patient 1 (Table 1). Still, it is impossible
to sequence every single part of a tumor, especially in a diagnostic setting.
Liquid biopsy is another option to detect different clones. However, liquid biopsy
highly depends on the amount of tumor cells in the blood. If this amount is low, the liquid
biopsy is likely to remain inconclusive. Moreover, not all clones of a heterogeneous primary
tumor may metastasize. Furthermore, it is possible to pick up clones in the blood that
originate from a completely different type of cancer (e.g., in a patient with both melanoma
and lung cancer). To find an optimal cost-benefit and effort-benefit ratio in the clinical
setting, it might be best to do NGS on whole sections of the tumor and disease monitoring
using liquid biopsy.
Several reports on the correlation of mutation status and immunotherapy outcome in
cutaneous melanoma have been published, but the results remain inconclusive. Kirchberger
et al. reported a similar response rate of both NRAS-mutant and wild type melanoma to
immunotherapy. However, median overall survival was significantly lower in the NRAS-
mutant group. Moreover, a treatment with MEK inhibitors could lead to a survival benefit
of NRAS-mutant patients [16]. Shoushtari et al. showed an inferior response of NRAS
p.Q61 mutant melanoma to anti-PD-1 monotherapy and a trend towards inferior response
to a combination of ipilimumab and nivolumab in cutaneous melanoma [17].
In contrast, Johnson et al. found a superior outcome of NRAS-mutant patients [18].
Since KRAS mutations are rare in melanoma, no results are available for immunotherapy
outcome in this group.
The effect of immunotherapy in mucosal melanoma was only investigated in a few
reports. However, it seems to be a promising treatment in this type of cancer with very
limited therapeutic alternatives. The overall response rate (ORR) to pembrolizumab in
mucosal melanoma was shown to be slightly lower than in cutaneous melanoma. However,
even CRs were reported [19] similar to our patient 2. When comparing treatment with
ipilimumab plus nivolumab in mucosal and cutaneous melanoma, the ORR rate was 37% in
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mucosal and 60% in cutaneous melanoma, respectively, showing that mucosal melanoma
patients may also benefit from this therapy [20]. Several studies reported a correlation of
response to immunotherapy and PD-L1 status in various types of cancer [21,22]. Never-
theless, in cutaneous melanoma also patients with negative PD-L1 status can respond to
IT, as shown by a previous study with an ORR of 54% and 72% in patients with negative
or positive PD-L1 status, respectively [23]. PD-L1 expression in mucosal melanoma is
less common than in cutaneous melanoma (44% positivity) as previously demonstrated
by Kaunitz et al. [24]. It even seems to be particularly low in the subtype of sinonasal
melanoma (20% positivity) [25], which is consistent with our previously published data [3]
and the observation in the present study. Still, two of our three patients responded to
this treatment.
In all three cases, CD8+ cells were present in the proximity of the tumor before IT
and infiltration was shown in resistant tumors. However, a slight increase of CD8+ cells
in the initially responding patients was evident in the NRAS mutant tumors, while the
intrinsic resistant patient showed a slight decrease of CD8+ cells. Whether the CD8+ T
cells in the NRAS mutant, IT-resistant tumors are exhausted, cannot be concluded from our
study. Moreover, with only three patients, it is not possible to draw statistically reliable
conclusions about CD8+ cell infiltration and response to IT.
Some associations of activated MAPK signaling and response to IT were recently made,
such as reduced T cell infiltration and activity, as shown in breast cancer [26]. Moreover,
NRAS is upstream of both MAPK and PIK3CA signaling, the latter being involved in
reduced CD8+ T cell infiltration and function [27].
Recent studies have shown a correlation of TMB and ORR to immune checkpoint
inhibitors. Nevertheless, mucosal melanoma patients, that generally have a lower TMB [28],
are able to respond to the treatment [20]. Similar to these findings, the TMB in our two
initially responding patients was low, while the intrinsic resistant patient had a slightly
higher TMB. Therefore, additional markers to TMB and PD-L1 may play a role in mu-
cosal melanoma.
Resistance to immunotherapy in melanoma is associated with alterations in the in-
terferon gamma pathway or a lack of MHC-I surface expression [8]. We did not detect
any alteration affecting the mentioned pathways with our custom NGS panel. While all
tumors within one patient shared several passenger mutations, no overlap of passenger
mutations among NRAS-mutant tumors was evident. Moreover, the morphology of the
NRAS-mutant tumors differed. This result is consistent with our previously reported lack
of morpho-molecular correlation in primary sinonasal melanoma [3].
Our study is limited by the lack of fresh material and patient-derived cell lines for
functional testing. Thus, we cannot prove a causal association between the emergence of
NRAS mutated clones and immunotherapy. In general, activating NRAS mutations could
be a survival advantage for sinonasal melanoma cells independent of therapy. However,
our finding can set the scene for future investigations to clarify the significance of the here
detected emerging NRAS mutations in the course of immunotherapy.
5. Conclusions
Our case series shows the importance of longitudinal testing, preferably by non-
invasive liquid biopsy, to monitor not only the presence, but also the change of driver
mutations in melanoma patients during the course of disease. Moreover, molecular testing
of larger tissue amounts (e.g., whole slide tissue) is preferable over tissue punches in
this entity to increase the chances of capturing heterogeneous tumors harboring different
relevant driver mutations. Our study also stresses the importance of regular whole-body
FDG-PET/CT imaging in the follow-up of sinonasal melanoma patients.
The awareness of the heterogeneity of primary sinonasal melanoma and the fact
that a unique driver switch may occur will help to adjust the treatment regimen in time
by combining immunotherapy and targeted therapy before the emergence of multiple
treatment-resistant metastases. Due to a lack of awareness, the occurrence of this issue can
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lead to significant discomfiture for pathologists and clinicians in charge and may have dire
consequences for patients.
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